HCW Biologics (HCWB) Cash from Investing Activities (2020 - 2024)
HCW Biologics' (HCWB) quarterly Cash from Investing Activities came in at -$113412.0 in Q4 2024, up 96.95% YoY from -$57584.8 in Q1 2024, and down 206.0% on a QoQ basis from -$37063.0 in Q3 2024.
HCW Biologics (HCWB) Cash from Investing Activities (2020 - 2024) Analysis & Trends
HCW Biologics (HCWB) has 5 years of Cash from Investing Activities data on file, last reported at -$113412.0 in Q4 2024.
- Quarterly Cash from Investing Activities rose 96.95% year-over-year to -$113412.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$113412.0 (up 97.06% YoY) and the FY2024 annual result came in at -$261617.0, down 106.89% from the prior year.
- Cash from Investing Activities fell to -$113412.0 in Q4 2024, from -$37063.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $9.4 million in Q3 2023 to a low of -$35.0 million in Q3 2021.
- A 5-year average of -$995079.2 and a median of -$37063.0 in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities sank 33138.35% — and 2022, when it jumped 34363.87%.
- Tracing HCWB's Cash from Investing Activities over 5 years: stood at -$36391.0 in 2020, then surged by 34.31% to -$23904.0 in 2021, then plunged by 187.35% to -$68687.0 in 2022, then slumped by 5309.54% to -$3.7 million in 2023, then jumped by 96.95% to -$113412.0 in 2024.
- The last three Cash from Investing Activities figures came in at -$113412.0 (Q4 2024), -$37063.0 (Q3 2024), and $18567.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -113,412.00 |
| Dec 31, 2024 | -113,412.00 |
| Sep 30, 2024 | -37,063.00 |
| Sep 30, 2024 | -37,063.00 |
| Jun 30, 2024 | 18,567.00 |
| Jun 30, 2024 | 18,567.00 |
| Mar 31, 2024 | -129,709.00 |
| Mar 31, 2024 | -129,709.00 |
| Dec 31, 2023 | -3.72 Mn |
| Dec 31, 2023 | -3.72 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Jun 30, 2023 | -1.56 Mn |
| Jun 30, 2023 | -1.56 Mn |
| Mar 31, 2023 | -300,385.00 |
| Mar 31, 2023 | -300,385.00 |
| Dec 31, 2022 | -68,687.00 |
| Dec 31, 2022 | -68,687.00 |
| Sep 30, 2022 | 6.81 Mn |
| Sep 30, 2022 | 6.81 Mn |